Patents by Inventor Hamid Band

Hamid Band has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20190374578
    Abstract: Methods and compositions for treating cancer, particularly improved CAR-T methods, are disclosed.
    Type: Application
    Filed: February 23, 2018
    Publication date: December 12, 2019
    Inventors: Hamid Band, Vimla Band, Fany Iseka, Bhopal Mohapatra, Matthew Storck
  • Cancer biomarkers and methods of use thereof
    Patent number: 9850313
    Abstract: Methods and compositions for treating cancer, particularly breast cancer, are disclosed.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: December 26, 2017
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Vimla Band, Hamid Band, Sameer Mirza
  • Cancer Biomarkers and Methods of Use Thereof
    Publication number: 20150203588
    Abstract: Methods and compositions for treating cancer, particularly breast cancer, are disclosed.
    Type: Application
    Filed: August 5, 2013
    Publication date: July 23, 2015
    Inventors: Vimla Band, Hamid Band, Sameer Mirza
  • Characterization of novel gene cbl-SL
    Patent number: 6867292
    Abstract: The invention pertains to nucleic acids encoding a cbl-SL protein, including fragments and biologically functional variants thereof. The invention also pertains to therapeutics and diagnostics involving the foregoing proteins and genes and agents that bind the foregoing proteins and genes.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: March 15, 2005
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Hamid Band, Francescopaolo Borriello
  • Human .gamma., .delta.T cell antigen receptor polypeptides and nucleic acids
    Patent number: 5185250
    Abstract: The present invention is directed to purified polypeptides comprising the .gamma. T cell antigen receptor (TCR) polypeptide, the .delta. TCR polypeptide, a .gamma., .delta. TCR complex, or a fragment thereof containing an epitope. The invention also relates to nucleic acid sequences encoding such polypeptides, and subsequences thereof. In specific embodiments, the invention relates to nucleic acid sequences comprising variable, diversity, joining, or constant regions of the .delta. TCR gene sequence. The invention also relates to monoclonal antibodies specifically reactive with an epitope of the gamma or delta TCR polypeptides. In specific embodiments, these antibodies are reactive with the delta constant region, the delta variable region, or gamma constant region. Such antibodies can be identified by detecting co-modulation of the CD3 antigen. In another embodiment, the invention relates to compositions comprising substantially purified cells which express both a .gamma., .delta. TCR and the CD4 antigen.
    Type: Grant
    Filed: January 13, 1989
    Date of Patent: February 9, 1993
    Assignees: T Cell Sciences, Inc., Dana Farber Cancer Institute, President & Fellows of Harvard College
    Inventors: Michael B. Brenner, Jonathan Seidman, Jack L. Strominger, Stephen H. Ip, Michael S. Krangel, Hamid Band